Hybrid immunity: the immune response of COVID-19 survivors to vaccination

• Published in: Bionatura Vol. 3; no. 3; pp. 1890 - 1892
• Main Authors: Gancino, Marlon, Santiago Vispo, Nelson
• Format: Journal Article
• Language: English
• Published: 15.08.2021
• ISSN: 1390-9347; 1390-9355
• DOI: 10.21931/RB/2021.06.03.1

Hybrid immunity can become a turning-point opportunity to defeat the infection in context with the current pandemic scenario. Adopting policies aligned with the data mentioned above may be particularly beneficial for regions like Latin America. While this region shares only ~5% of the world population, it accumulates +16% of the ~200 million COVID-19 total cases, so far reported1. Acknowledging the reduced diagnostic capabilities of these countries, this entire area is probably one of the most affected globally, leading to one of the more numerous populations of convalescent people. From both an economic and pharmacological perspective, applying a one-dose regime of pertinent vaccines to convalescent individuals is sustainable5. As COVID-19 survivors may need just one vaccination to achieve high levels of protective immunity, massive antibody screening for SARS-CoV-2 spike antibodies could help prioritize and free up doses, optimize vaccine supply efficiency, and surpass problems linked to the current vaccine manufacturing bottleneck